Asia Pacific Breast Adenocarcinoma Treatment Market Size & Outlook
The breast adenocarcinoma treatment market in Asia Pacific is expected to reach a projected revenue of US$ 10,585.2 million by 2030. A compound annual growth rate of 9.8% is expected of Asia Pacific breast adenocarcinoma treatment market from 2024 to 2030.
Revenue, 2023 (US$M)
$5,510.5
Forecast, 2030 (US$M)
$10,585.2
CAGR, 2024 - 2030
9.8%
Report Coverage
Asia Pacific
Asia Pacific breast adenocarcinoma treatment market highlights
- The Asia Pacific breast adenocarcinoma treatment market generated a revenue of USD 5,510.5 million in 2023.
- The market is expected to grow at a CAGR of 9.8% from 2024 to 2030.
- In terms of segment, chemotherapy was the largest revenue generating treatment in 2023.
- Chemotherapy is the most lucrative treatment segment registering the fastest growth during the forecast period.
Asia Pacific data book summary
| Market revenue in 2023 | USD 5,510.5 million |
| Market revenue in 2030 | USD 10,585.2 million |
| Growth rate | 9.8% (CAGR from 2024 to 2030) |
| Largest segment | Chemotherapy |
| Fastest growing segment | Chemotherapy |
| Historical data covered | 2018 - 2022 |
| Base year for estimation | 2023 |
| Forecast period covered | 2024 - 2030 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Chemotherapy |
Other key industry trends
- In terms of revenue, Asia Pacific region accounted for 23.6% of the global breast adenocarcinoma treatment market in 2023.
- Globally, North America is projected to lead the regional market in terms of revenue in 2030.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 10,585.2 million by 2030.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Breast Adenocarcinoma Treatment Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Eli Lilly and Company | View profile | - | - | - |
| F. Hoffmann-La Roche Ltd. | View profile | - | - | - |
| Bristol Myers Squibb | View profile | - | - | - |
| Kyowa Kirin Co Ltd | View profile | 5974 | 1-9-2,Otemachi, Chiyoda-ku, Otemachi Financial City Grand Cube, Tokyo, Japan, 100-0004 | http://www.kyowa-kirin.com |
| Eisai Co Ltd | View profile | 11076 | 4-6-10 Koishikawa, Bunkyo-ku, Tokyo, Japan, 112-8088 | http://www.eisai.co.jp |
| AstraZeneca PLC | View profile | 89900 | 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, United Kingdom, CB2 0AA | https://www.astrazeneca.com |
| Merck & Co Inc | View profile | 72000 | 126 East Lincoln Avenue, Rahway, NJ, United States, 07065 | https://www.merck.com |
| Sanofi SA | View profile | 87994 | 46, avenue de la Grande Armée, Paris, France, 75017 | https://www.sanofi.com |
| Pfizer Inc | View profile | 88000 | 66 Hudson Boulevard East, New York, NY, United States, 10001-2192 | https://www.pfizer.com |
| Novartis AG ADR | View profile | 76057 | Lichtstrasse 35, Basel, Switzerland, 4056 | https://www.novartis.com |
Related industry reports
Related statistics
No records
No related statistics found.
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
